Plain-English translation of NCT06269146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether pramipexole, a medication that increases dopamine signaling in the brain, can help people with anxiety or depression feel more motivated to connect socially with others. The study will measure how the medication affects your brain's response to social interactions and how you feel about connecting with people. Researchers believe that by boosting dopamine, this treatment might help reduce the sense of social disconnection that often comes with anxiety and depression.
Many people with anxiety or depression struggle to feel motivated to build and maintain friendships and social relationships. This trial exists to test whether targeting dopamine—a brain chemical involved in reward and motivation—could be a new way to help people feel more drawn to positive social interactions and less isolated.
You will take a capsule twice daily for 6 weeks—either the study medication at one of two doses or a placebo (inactive pill). You cannot tell which one you're receiving. You'll visit the research clinic at the start and after 6 weeks, where you'll complete brain imaging (fMRI), answer questions about your social experiences, and participate in tasks that measure how you respond to social cues. The study is designed to be manageable around your regular schedule.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States